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V(D)J recombination and formation of excision circles
-----------------------------------------------------

Thymus and bone marrow (BM) are the primary anatomic sites for new T- and B-cell generation from undifferentiated hematopoietic precursors (Figure [1](#F1){ref-type="fig"}). Throughout this process, a highly heterogeneous lymphocyte repertoire is generated allowing the resulting cells to respond to a wide variety of antigenic stimuli \[[@B1]-[@B3]\]. Physiologically, T-cell maturation in the thymus progresses through distinct stages that are phenotypically defined by the expression of the T-cell receptor (TR) and the CD4 and CD8 co-receptors. On the basis of a programmed expression of distinct cell surface markers and of ordered gene rearrangements, thymocytes undergo different maturation steps before reaching the end stage \[[@B4]\]. B-lymphocyte development is divided into two main phases: an initial antigen-independent phase, in which precursor B cells mature into functional B lymphocytes in the BM, and an antigen-dependent phase, in which the mature B-cell compartment is maintained by regeneration, turnover and selection processes \[[@B5]\].

![**New T- and B-cell generation.A**) Lymphoid progenitors migrate to the thymus, where they progressively rearrange T-cell receptor (*TR*) genes. Before the rearrangements of the *TR*alpha (*TRA*) locus, the *TR*delta (*TRD*) locus, which lies within the *TRA*locus, must be excised by DNA recombinations. Among them, the δREC--ψJα recombination, which occurs in about 70% of thymocytes \[13\], leads to the generation of a δREC--ψJα coding joint (CJ) in the chromosome and of a δREC--ψJα signal joint (SJ) in a circle of DNA called TR excision circle (TREC). Maturing thymocytes undergo 3--4 intrathymic divisions, in which TRECs cannot be duplicated; thus, only a fraction (about 1:8--1:16) of the originally TREC^+^cells will leave the thymus as TREC^+^recent-thymic emigrants (RTE) \[6,13,15\]. Peripheral proliferation will determine further TREC dilution. **B**) In the bone marrow, progenitor B cells undergo *V(D)J*rearrangements of the Ig heavy chain (*IGH*) locus followed by those of the light chains (*IGK*and *IGL*). After successful *IGH*rearrangements at the Pre-B stage, a *VJ* recombination on the *IGK*locus is initiated. If it is not productive, another recombination between the Ig kappa deleting element or like (IGKDEL) and one of the upstream recombination signal sequences (RSS) renders the *IGK*allele non-functional. In 30%-50% of cases, this occurs through the intronRSS-IGKDEL rearrangement, by which the *IGKC*exon and its enhancers (iEκ, 3'Eκ) are excised, with the creation of the so-called kappa-deleting recombination excision circles (KRECs). Thus, KRECs carry an intronRSS-IGKDEL SJ, and remain in the cells, but, as they cannot be replicated, they will be diluted during peripheral expansion of mature B cells. Instead, an intronRSS-IGKDEL CJ is formed and stably retained in the genomic DNA \[7,8,10\], because, due to the enhancer loss, any further rearrangement in the *IGK*locus is precluded.](1479-5876-11-119-1){#F1}

During the maturation processes of TR alpha/beta chains and of B-cell receptor (BcR) heavy and light chains, genomic rearrangements of antigen receptor genes generate functional receptors. This process is necessary because the gene complexes encoding the TR and BcR components do not contain a functional first exon, while including multiple variable (V), diversity (D), and joining (J) genes. In the antigen-independent differentiation phase, stepwise rearrangements are introduced into the genome to couple one of each segment together to form a functional first exon. The rearrangement of the TR alpha (*TRA*) genes has the peculiarity of involving the excision of delta-coding segments that, being nestled in the *TRA* locus between the *TRAV* and *TRAJ* genes, must be removed in order to allow the generation of the TRA chain. The excised DNA is circularized due to the ligation of the blunt DNA signal ends, thereby forming a signal joint (SJ) within the stable circular excision products termed TR excision circles (TRECs) \[[@B6]\]. Therefore, TRECs are the excised DNA circles formed during the process of TRA chain *VJ* recombination (Figure [1](#F1){ref-type="fig"}A). In B-cell maturation, K-deleting recombination excision circles (KRECs) are the products of recombination events determining the allelic and isotypic exclusion of the Ig kappa (*IGK*) locus \[[@B7]-[@B9]\]. They are created in those B lymphocytes that, after completing the IG heavy gene rearrangement, have failed to productively rearrange *IGK* genes on one or both alleles \[[@B10]\]. In these cells, the *IGK* locus becomes non-functional through the deletion of the *IGK* constant gene (*IGKC*) resulting from the recombination of the Ig kappa deleting element or like (IGKDEL), which is a sequence located approximately 24 kb downstream of the *IGKC*, with one of the upstream recombination signal sequences (RSS) located either at the 3' side of a *IGK* variable gene segment (*IGKV*) or in the intron between the *IGK* joining segments (*IGKJ)* and the *IGKC*\[[@B10]\]. When the IGKDEL recombines with the RSS located in the *IGKJ-IGKC* intron (intronRSS), the formation of a coding joint (CJ) precludes any further rearrangements in the *IGK* locus. Thus, the CJ remains present in the genome, whereas an intronRSS-IGKDEL SJ is formed in the portion of DNA that is removed, thus forming the excision circle KREC (Figure [1](#F1){ref-type="fig"}B) \[[@B7],[@B8]\].

Quantification of TRECs and KRECs
---------------------------------

Assays for quantification of TRECs and KRECs in peripheral blood are now performed in clinical and research laboratories to monitor naive T and B cells emigrating from the thymus and BM, respectively. Although TRECs are not markers of recent thymic emigrants by definition, because a small part remains present in peripheral blood in the so-called "old" thymic emigrants \[[@B6],[@B11]-[@B14]\], several properties identify them as "bona fide" useful markers of thymic output. They are stable, do not replicate upon cell division and therefore are diluted in the progeny, do not degrade easily over time, and are (almost) exclusively of thymic origin, without extrathymic sources of *TR* rearrangements \[[@B6]\]. In particular, approximately 70% of T cells differentiating in the thymus contain TRECs \[[@B11]\], before being diluted 1:8--1:16 because of intrathymic divisions occurring during the last steps of maturation \[[@B13],[@B15]\]. The TREC quantitative assay, initially proposed by Douek DC et al. \[[@B6]\], has been later modified in different ways and TREC number has been evaluated in different biological samples or calculated by different approaches, resulting into hardly comparable results. In fact, a more accurate TREC measurement has been obtained when quantification was performed relative to a control gene, such as chemokine (C-C motif) receptor 5, albumin, or *TRA* constant (*TRAC*) gene \[[@B12],[@B16],[@B17]\]. Furthermore, TREC content in peripheral blood has been reported either relative to peripheral blood mononuclear cells (PBMC), or quantified within sorted individual T-cell subsets \[[@B12],[@B18]\]. In addition, the quantity of TRECs has been expressed either as absolute number of TREC molecules per μg of DNA within PBMC or T lymphocytes \[[@B16],[@B19],[@B20]\], or per 10^6^ cells, on the basis of the theoretical recovery of 1 μg of DNA from approximately 150,000 cells \[[@B21],[@B22]\]. Because in adults' samples TREC calculation per 10^6^ PBMC can lead to erroneous interpretations due to the diluting effect of peripheral T-cell divisions, this limitation has been, at least in part, overcome by expressing TRECs per ml of blood \[[@B23],[@B24]\]. Finally, in spite of the present lack of information regarding TREC half-life \[[@B13]\], several mathematical models, which have taken into consideration confounders such as cell death, longevity of naive T cells, and intracellular degradation, have been recently proposed to identify the actual thymic output as a function of the TREC number \[[@B22],[@B24]\].

Scanty information are presently available regarding the quantification of KRECs. Because the CJ remains in the genome, whereas the SJ present in the KREC is diluted after each cell division, the difference between the cycle threshold (Ct) values of the SJ and the CJ, obtained by real-time PCR, has been initially exploited to calculate the average number of divisions in a pool of B cells. In particular, because the intronRSS-IGKDEL rearrangement occurs late during BM differentiation, this measure is a good estimate of the average number of divisions performed by mature B cells after leaving the precursor B-cell compartment \[[@B7]\]. Furthermore, the frequency of B-cells that contain an intronRSS--IGKDEL rearrangement can be determined when a control gene is quantified together with the CJ \[[@B8]\]. A modified technique was used to determine the number of developing B lymphocytes in the BM of children with B-precursor acute lymphoblastic leukemia treated with allogeneic human stem-cell transplantation (HSCT) \[[@B25]\]. In this assay, KRECs were calculated by using the ΔCt method with a calibrator sample and by correcting the quantity and quality of DNA in the samples employing albumin as reference gene. The final number of KRECs relative to the calibrator was expressed as: 2^Ctcalibrator-Ctsample + log2(DNAconc. calibrator/DNAconc. sample)^.

More recently, we modified this newly proposed KREC assay and the widely used TREC assay by setting up a duplex quantitative real-time PCR that, by measuring together TRECs and KRECs, allows the quantification of newly produced T and B lymphocytes \[[@B26],[@B27]\]. The main advantage of the combined assay is that the variability related to direct DNA quantification is eliminated by the use of a unique standard curve obtained by diluting the triple-insert plasmid, which contains TREC, KREC and *TRAC* fragments in a 1:1:1 ratio \[[@B26]\]. The last serves as a control for both the quality and quantity of genomic DNA in the sample. Furthermore, the simultaneous quantification of the two targets in the same reaction, results into a containment of laboratory costs. The duplex TREC/KREC assay is performed on DNA extracted from PBMC isolated from heparinized blood using primers and probes specific for TRECs, KRECs and *TRAC*. TRECs or KRECs per 10^6^ PBMC are calculated as the ratio between the mean number of TRECs or KRECs and the mean copy number of *TRAC* divided by 2, which is the number of *TRAC* copies per cell, and multiplied by 10^6^. This value, in conjunction with the combined lymphocyte - monocyte number in one ml of blood (which are the cells contained in a PBMC preparation), is used to calculate the number of TRECs or KRECs per ml of blood (TRECs or KRECs per 10^6^ PBMC) × (lymphocyte plus monocyte count in one ml of blood)/10^6^\[[@B26]\].

TRECs and KRECs as markers of primary and acquired immunodeficiencies
---------------------------------------------------------------------

TREC level has been extensively assayed in children with primary immunodeficiencies (PID) in whom the decreased number and function of T and/or B cells result into significant impairment of immunity. These rare, genetically determined disorders, which characteristically manifest during infancy and childhood with increased frequency of infections caused by unusual pathogens, are often accompanied by immunoregulatory defects \[[@B28]\]. Severe combined immunodeficiency (SCID), the most serious and lethal form of PID, is characterized by profound deficiencies of T- and B-cell functions and a low number of natural killer (NK) cells \[[@B29],[@B30]\]. Infants with SCID develop failure to thrive, chronic diarrhea, and infections in the first few months of life. Graft-versus-host disease (GVHD), caused by maternal T-cell engraftment, may occur in these patients, who also show skin rash and organomegaly. All infants with the typical form of SCID, as well as those with another form of SCID, known as the Omenn syndrome, show extremely low or undetectable TREC levels (see Table [1](#T1){ref-type="table"}, which completes and extends the data reported by van Zelm et al.) \[[@B8],[@B26],[@B31]-[@B42]\]. Despite the normal number of circulating T cells, abnormally low TREC levels were also observed in patients with zeta-chain (TCR) associated protein kinase 70kDa (ZAP70) deficiency and with the 22q11.2 deletion syndrome, especially in those without an identifiable thymus \[[@B31],[@B38]\]. In contrast, patients with mutations in CD40 ligand, forkhead box protein 3 (*FOXP3*), and interleukin 10 receptor alpha chain, as well as patients with the p.R222C mutation in the interleukin 2 receptor gamma gene, display normal TREC levels \[[@B31]\]. As in SCID patients, the TREC assay contributed to understand the pathophysiology of other PID such as CD4^+^ T lymphocytopenia. In these patients, TREC levels correlated to the severity of the T-cell immunodeficiency \[[@B43]\]. Finally, TREC quantification has been used to improve our understanding of the T-cell abnormality that is sometimes observed in common variable immunodeficiency (CVID), although its precise role in this condition is still a matter of debate. While in fact some authors reported that the median TREC level in these patients was significantly higher than in healthy subjects, others found that this number was significantly reduced, in particular in patients characterized by a low number of switched/memory B cells (sIgD^-^CD27^+^), by a large proportion of CD19^hi^CD21^lo^ cells, and by an increased risk of autoimmunity and splenomegaly \[[@B41],[@B44]-[@B46]\].

###### 

T- and B-cell immunodeficiencies in which TRECs and KRECs have been evaluated

  **Disease**      **Genetic defect**            **TRECs**    **KRECs**                                        **Author**
  ---------------- ---------------------------- ------------ ----------- --------------------------------------------------------------------------------------
  SCID             *ADA*                             ↓           nd              Roifman \[[@B31]\]; Gerstel-Thompson \[[@B32]\]; Morinishi \[[@B33]\]
                   *AK2*                             ↓            ↓                                         Borte \[[@B34]\]
                   *CD3G*                            ↓           nd                                        Roifman \[[@B31]\]
                   *CD8A*                            ↓            ↓                                        Sottini \[[@B26]\]
                   *IL2RA*                           ↓           nd                                        Roifman \[[@B31]\]
                   *IL2RG*                           ↓            ↑       Roifman \[[@B31]\]; Morinishi \[[@B33]\]; Borte \[[@B34]\]; Chan and Puck \[[@B35]\]
                   *JAK3*                            ↓            ↑        Morinishi \[[@B33]\]; Borte \[[@B34]\]; Chan and Puck \[[@B35]\]; Hale \[[@B36]\]
                   *LIG4*                            ↓           nd                             Roifman \[[@B31]\]; Morinishi \[[@B33]\]
                   *PNP*                             ↓           nd                                   Gerstel-Thompson \[[@B32]\]
                   *RAG1*                            ↓            ↓          Sottini \[[@B26]\]; Roifman \[[@B31]\]; Morinishi \[[@B33]\]; Borte \[[@B34]\]
                   *RAG2*                            ↓           nd                             Roifman \[[@B31]\]; Morinishi \[[@B33]\]
                   *RMRP*                            ↓           nd                                        Roifman \[[@B31]\]
                   *ZAP70*                           ↓           nd                                        Roifman \[[@B31]\]
                   *IL7RA*                           ↓            ↑                                         Borte \[[@B34]\]
                   unclassified                      ↓            ↓                               Roifman \[[@B31]\]; Borte \[[@B34]\]
                   *CD40LG*                          ↑            ↑                     Sottini \[[@B26]\]; Roifman \[[@B31]\]; Borte \[[@B34]\]
                   *FOXP3*                           ↑           nd                                        Roifman \[[@B31]\]
                   *IL10RA*                          ↑           nd                                        Roifman \[[@B31]\]
                   *IL2RG* (p.R222C mutation)        ↑           nd                                        Roifman \[[@B31]\]
                   partial *ADA*                     ↑           nd                                        Roifman \[[@B31]\]
  DGS              22q11.2 deletion                  ↓           nd                                Routes \[[@B37]\]; Lima \[[@B38]\]
  NBS              *NBN*                             ↑            ↓                            Borte \[[@B34]\]; van der Burg \[[@B39]\]
  XLA              *BTK*                             ↑            ↓                              Borte \[[@B34]\]; Nakagawa \[[@B40]\]
  non-XLA                                            nd           ↑                                       Nakagawa \[[@B40]\]
  AT               *ATM*                         borderline       ↓                                         Borte \[[@B34]\]
  WAS              *WAS*                             ↓            ↓                                        Sottini \[[@B26]\]
  CVID (adults)                                      ↓            ↓                                        Serana \[[@B41]\]
  CVID (newborn)                                     ↑            ↑                                Borte \[[@B34]\]; Kamae \[[@B42]\]
  IgAD                                               ↑            ↑                                         Borte \[[@B34]\]

*ADA*: adenosine deaminase; *AK2*: adenylate kinase 2; *AT*: ataxia-telangectasia; *ATM*: AT mutated; *BTK*: Bruton agammaglobulinemia tyrosine kinase; *CD3G*: CD3g molecule, gamma (CD3-TCR complex); *CD40LG*: CD40 ligand; *CD8A*: CD8A molecule; CVID: common variable immunodeficiency; DGS: DiGeorge syndrome; *FOXP3*: forkhead box P3; IgAD: IgA deficiency; *IL10RA*: interleukin 10 receptor, alpha; *IL2RA*: interleukin 2 receptor, alpha; *IL2RG*: interleukin 2 receptor, gamma; *IL7RA*: interleukin 7 receptor, alpha; *JAK3*: Janus kinase 3; KRECs: k-deleting recombination excision circles; *LIG4*: ligase IV, DNA, ATP-dependent; *NBN*: nibrin; NBS: Nijmegen breakage syndrome; nd: not done; *PNP*: purine nucleoside phosphorylase; *RAG1*: recombination activating gene 1; *RAG2*: recombination activating gene 2; *RMRP*: RNA component of mitochondrial RNA processing endoribonuclease; SCID: severe combined immunodeficiency; TRECs: T-cell receptor excision circle; *WAS*: Wiskott-Aldrich syndrome; XLA: X-linked agammaglobulinemia; *ZAP70*: zeta-chain (TCR) associated protein kinase 70kDa.

↑: over the cut-off; ↓: lower than the cut-off or undetectable.

KREC level has been evaluated only very recently in children with PID, and mainly in patients affected by X-linked or non X-linked agammaglobulinemia (XLA and non-XLA, respectively), and in those with CVID. While XLA, the most severe form of B-cell defects, results from a mutation in the Bruton agammaglobulinemia tyrosine kinase (*BTK)* gene that causes a B-cell differentiation arrest in the BM, with consequent absence of mature B cells and serum Ig, non-XLA is characterized by hypogammaglobulinemia with decreased B-cell counts in the absence of the *BTK* gene mutation \[[@B47]\]. In both forms, which account for about 20% of all B-cell defects, recurrent infections appear between 3 and 18 months of age \[[@B48]\]. KREC measurement has been proposed as a potential tool for the identification of these two diseases, because B-cell maturation defects occur before IGKDEL events, and therefore KRECs should be not produced/detected in these patients. Indeed, a study performed by analyzing KRECs derived from dried blood spots revealed that no KRECs were detected in 30 XLA and 5 non-XLA patients \[[@B40]\]. We employed the combined TREC/KREC assay to measure the extent of T- and B-cell neoproduction in CVID adult patients with no acute infections and undergoing Ig passive immunotherapy. The number of TREC^+^ lymphocytes, which depended on age and gender, was significantly reduced. At the same time, KREC number was lower than in controls, but it did not change with age and was not influenced by the gender. Of note, 35% of CVID patients had less KRECs/ml than the 5^th^ percentile calculated in controls \[[@B41]\]. On the contrary, newborns affected by CVID (and those with some other typical SCID, see Table [1](#T1){ref-type="table"}) displayed a number of KRECs comparable to that of healthy newborns \[[@B34]\]. Very recently, Kamae et al. \[[@B42]\] showed that the amount of TRECs and KRECs can be a useful marker to assess the pathogenesis and clinical severity of CVID in distinct patients.

While the quantification of TRECs has been performed for years and is used as a surrogate marker of thymic output in HIV-infected patients \[[@B6]\], the precise interpretation of TREC data obtained in acquired immunodeficiency subjects is more challenging. Indeed, it depends heavily on the assumed fate of naive T cells, recent thymic emigrants in particular \[[@B12],[@B24],[@B49]\], and on the different clinical-pathological parameters of infected subjects, such as age and plasma HIV-1 RNA. Although several studies have shown that HIV-infected subjects have a lower number of TRECs than that found in age-matched uninfected individuals \[[@B6],[@B12],[@B16],[@B50]\], the TREC number is variable among patients and overlaps with that of controls \[[@B16]\]. Using the TREC/KREC assay we found that the number of TREC^+^ cells of patients that need antiretroviral therapy was significantly lower not only when compared to controls, but also when compared to HIV-infected patients with a relatively conserved CD4 cell number and not requiring treatment according to the current guidelines. In this latter group, the number of KRECs was significantly higher than that found in patients needing treatment, but similar to that found in age-matched healthy controls \[[@B51]\].

TREC/KREC assay for detection of neonatal primary immunodeficiency diseases
---------------------------------------------------------------------------

Early recognition of SCID should be considered a pediatric emergency, because a diagnosis before the vaccination programs and the onset of recurrent infections allows lifesaving HSCT, enzyme replacement, or gene therapy \[[@B52]-[@B60]\]. Similarly, early diagnosis and treatment, including periodical intravenous Ig replacement therapy, are essential to improve the prognosis and the quality of life of patients with B-cell defects. However, infants with SCID or agammaglobulinemia often appear normal at birth, have no family history of immunodeficiency \[[@B61]\], and, consequently, many of them are not identified until life-threatening infections occur.

The demonstration that the TREC assay detects SCID patients regardless of the underlying genetic defects \[[@B33]\] and that agammaglobulinemia patients can be identified with KREC quantification \[[@B40]\], suggested that the TREC and KREC assays can be used for the detection of SCID and agammaglobulinemia in newborn screening (NBS) programs. This is particularly true for SCID, which satisfies the criteria recommended by the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children \[[@B62]\]. The TREC assay was the first to be modified and calibrated to allow the test to be performed on DNA extracted from small spots of dried blood, to be highly sensitive and specific for SCID, cost-effective, reproducible and, therefore, amenable to be used in a population-based screening \[[@B63]\]. Pilot studies of NBS for SCID, integrated with diagnosis and management guidelines, have been performed in some U.S. states \[[@B61]\]. Accordingly, in 2008, Wisconsin became the first state to implement mandatory NBS for T-cell deficiencies \[[@B37]\], followed, in February 2009, by Massachusetts \[[@B32],[@B64]\] and, later, by New York, Navajo Nation, California, Puerto Rico and Louisiana \[[@B65]\]. By using in-house modifications of the TREC assay (with the exception of California, where a TREC assay kit under development by a company was used), these pilot studies identified, among the 961,925 newborns screened, several cases of T-cell deficits, 14 of which resulted to be SCID at the confirmatory tests, 6 SCID variants, and 40 T-cell lymphopenia not related to SCID \[[@B32],[@B35],[@B63]-[@B65]\]. All infants with SCID identified in Wisconsin and Massachusetts have undergone transplantation or enzyme replacement therapy and are all alive \[[@B36],[@B37]\]. More recently, also the TREC/KREC assay was modified, making it suitable to be performed on a single Guthrie card punch. This assay has been validated in a cohort of 2,560 NBS cards from healthy neonates and used to identify patients with SCID, XLA, ataxia-telangiectasia, and Nijmegen-breakage-syndrome \[[@B34]\]. The early diagnosis of children with XLA is expected to significantly improve their quality of life and contribute to a reduction of health care costs. Indeed, because their clinical phenotype is less severe than that in SCID, the risk of undiagnosed disease in their first years of life in absence of a screening program would foster the development of more severe organ damage.

Conclusively, considering that the TREC measurement is performed at the relatively low cost of approximately \$ 5.50 per assay \[[@B37]\], that the inclusion of KREC detection in the TREC assay barely increases the costs, and that SCID and agammaglobulinemia have a combined estimated incidence of 1:30,000-1:50,000 births, a single assay capable of screening for both conditions should further improve the cost-effectiveness of the NBS for PID. The importance of introducing PID in NBS programs has been underlined by the guidelines very recently proposed by Borte et al. \[[@B66]\].

Quantification of TRECs and KRECs for therapy monitoring of primary and acquired immunodeficiencies
---------------------------------------------------------------------------------------------------

Patients with SCID have a very short life-expectancy if they are not promptly treated with HLA-identical or HLA-haploidentical HSCT \[[@B67],[@B68]\], which frequently results into a durable engraftment of all hematopoietic cell lineages that leads to a restoration of immunological functions in the absence of GVHD \[[@B68],[@B69]\]. Therefore, the success of HSCT mainly depends on the rate of cellular immune reconstitution \[[@B70]-[@B75]\]. However, while innate immunity shows a full phenotypic and functional recovery within a month from transplantation \[[@B76]\], the recovery of T cells can be significantly delayed, even in comparison to that of B cells, which can occur within 6--9 months (although a fully functional reconstitution encompassing the synthesis of all Ig isotypes may require up to 2 years) \[[@B76]-[@B80]\]. Therefore*,* due to the impairment of both T- and B-cell functions, HSCT recipients are more prone to infections and relapse of malignancies \[[@B81],[@B82]\], and the risk of developing these complications notably correlates with the recovery of CD4^+^ T cells \[[@B83]\]. Because it is known that, in these patients, the appearance of TRECs is the most predictive indicator for long-term T-cell reconstitution \[[@B84]\], a frequent monitoring of the T-cell immunity and TREC number after HSCT can help identify those patients who will eventually fail to be properly reconstituted, thus requiring additional therapies that could be more timely initiated. The use of the TREC assay may be also relevant to verify the outcome of unconditioned transplantations with matched sibling and family donors. In these cases, which are highly successful in terms of survival outcome, the assay may be informative in detecting a long-term thymopoiesis, or to establish whether the T-cell reconstitution is due to an engraftment of mature T cells that will ultimately be exhausted, thus leading to a long-term T-cell deficiency \[[@B83]\]. Indeed, a low TREC number has been found after unconditioned procedures, indicating the occurrence of only a limited prethymic progenitor-cell engraftment. Therefore, in these transplantations, the long term T-cell immunity is likely to be sustained by a pool of mature T cells \[[@B85]\]. Finally, the progressive decline of thymopoiesis observed after HSCT has been attributed to a number of factors. These include: a defective thymic microenvironment, which is derived from pre-existing alterations or GVHD-induced damages; the lack of an adequate reservoir of healthy donor stem cells (associated with the lack of conditioning); an insufficient HSC dose; or the recipient's age \[[@B83],[@B86],[@B87]\].

The long-term (functional) immune recovery was particularly difficult to assess in Adenosine deaminase (ADA)-SCID patients. Treatments of these patients have included HSCT from an HLA-identical sibling donor without conditioning regimen, when available \[[@B88]\], enzyme replacement therapy \[[@B89]\], transplantation with unrelated donor cells \[[@B88]\], and gene therapy \[[@B90],[@B91]\]. Using the TREC/KREC assay, we conducted a detailed evaluation of T- and B-cell reconstitution in patients with broadly overlapping immunologic parameters, treated with HSCT or with polyethylene glycol-conjugated (PEG)-ADA. We found that the TREC level rose in both groups, but then quickly declined and persisted at low levels in the PEG-ADA group. The B-cell generation, studied both by B-cell subset phenotyping and KREC quantification, was more often impaired in the PEG-ADA group, and homeostatic proliferation could only partly compensate the decreased BM output \[[@B27]\].

TRECs/KRECs were also measured in patients with other PID (SCID T^-^B^-^NK^+^, SCID T^-^B^-^NK^-^, SCID T^-^B^+^NK^+^, SCID T^-^B^+^NK^-^, X-linked hyper IgM, Wiskott-Aldrich syndrome and familial hemophagocytic lymphohistiocytosis) who underwent HSCT and were followed up for a period ranging from 12 to 79 months. These children were heterogeneous with respect to sex, immunodeficiency type, graft donor, age of the donors and recipients of HSCT, type of conditioning, and occurrence and grade of GVHD. We found that the post-transplantation increase of TRECs and KRECs could be either strictly associated or independent of each other, and it was followed by the normalization of the T-cell repertoire and Ig production. Some patients showed a sharp, but transitory increase in new lymphocyte output which declined later on; in other patients, the TREC and KREC number remained very low for the entire period of surveillance \[[@B26]\].

An early output of B and T lymphocytes from the production and maturation sites, which is indicative of successful clinical outcome, was demonstrated, using a similar approach, also in transplanted SCID patients with a deficient recombination-activating gene 2 \[[@B92]\].

The TREC assay was also extensively used to evaluate the immune reconstitution in HIV-infected patients treated with antiviral therapy \[[@B6],[@B93]-[@B96]\]. Common knowledge is that thymic immune reconstitution of HIV-infected patients is more successful in children than in adults, suggesting that increased thymic output could play, at least in the formers, a predominant role in immune recovery \[[@B97]\]. TREC number increases in both virological responder and non-responder children, indicating that the persistence of viremia during therapy does not impair the increase in thymic function and the subsequent output of naive cells \[[@B98]\]. In adult patients with HIV-related lymphoma highly responder to antiretroviral therapy, the analysis of the kinetics and the extent of T-cell reconstitution before and after HSCT demonstrated that the very low level of TRECs before transplantation significantly increased following treatment \[[@B99]\], due to an extent of immune recovery close to that observed in transplanted HIV-negative patients with lymphoma \[[@B100]\]. Similarly, TREC monitoring in HIV-infected patients, long-term treated with low-doses of recombinant human growth hormone therapy, showed a recovery of thymopoiesis, as confirmed also by thymic index, density and area quantification \[[@B101]\]. Only few data are available on the number of KRECs in treated HIV-infected patients. One year of therapy did not modify the KREC number, while the long-lasting treatment (6 years) resulted in a significant decrease in new B-cell release from the BM \[[@B51]\]. However, due to the scarcity of available data, the usefulness of KREC quantification in these patients remains to be firmly established.

Limitations of the use TRECs and KRECs as immunological markers of immunodeficiency
-----------------------------------------------------------------------------------

Because TRECs and KRECs are not produced if maturation of T cells and B cells ceases at early steps, they are diluted out after cell division, they can persist in old thymic emigrant cells, and they disappear after cell death, caution is warranted in interpreting their number in the clinical setting. Therefore, even though expressing the amount of TRECs or KRECs per ml of blood overcomes the issue of peripheral dilution \[[@B24],[@B102]\], this measurement alone cannot still be considered a direct clinical marker of immune disease. Indeed, TRECs can be decreased in subjects that are not immunodeficient, such as premature babies and Down syndrome patients \[[@B103],[@B104]\]. Therefore, it must be also emphasized that TREC/KREC determination is only the first-tier assay, that must be followed by appropriate second-tier assays defining the disease (if any) that results in the low TREC/KREC values.

Conclusions
===========

The increasing laboratory and clinical evidences reported in this review, which extends and completes the recent one by van Zelm et al. \[[@B8]\], indicate that the quantification of TRECs and KRECs can be very informative in the management of patients with primary and acquired immunodeficiencies. It appeared that it is technically feasible to introduce the TREC/KREC assay into routine laboratory practice both for NBS and for a more critical monitoring of the rate of T- and B-cell immune reconstitution following HSCT and antiretroviral therapy.
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